• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Clinical trials roundup: Medtronic study to boost CRT-D industry?

Clinical trials roundup: Medtronic study to boost CRT-D industry?

November 15, 2010 By MassDevice staff

Clinical trials roundup

Cardiac resynchronization-therapy defibrillators reduced the mortality rate by 29 percent in patients with mild symptoms of heart failure, according to a study released by Medtronic Inc. (NYSE:MDT) at the annual meeting of the American Heart Assn. in Chicago.

The landmark study could prove to be a boon for not only for the Fridley, Minn.-based medical device monolith, but also for other big names in the CRT-D space, such as Boston Scientific Corp. (NYSE:BSX) and St. Jude Medical Inc. (NYSE:STJ).

The nearly 1,800-patient study examined subjects with mild-to-moderate symptoms of heart failure in Canada, Europe, Turkey and Australia for at least 18 months and for an average of 40 months. Mortality alone and combined mortality/hospitalization rates slid by 25 percent compared with patients treated with implantable cardiac defibrillators, according to the study, which was also published in the New England Journal of Medicine.

Cardiologists believe the device can help promote "reverse remodeling." The left ventricles of patients with cardiac failure often become enlarged; CRT-D devices can help reduce the size of such patients’ hearts and improve the function of the left ventricle.

In an editorial on the study in the NEJM, Dr. Arthur Moss of the University of Rochester School of Medicine and Dentistry called the results "indeed breathtaking," but cautioned that "device- or implant-related complications and device-related hospitalizations during follow-up were twice as frequent in the ICD–CRT group as in the ICD group."

The study also raises an economic question: Who will pay for the devices, which cost about $10,000 more than standard ICDs, according to the Wall Street Journal.

“How is this going to get funded, and who’s going to pay for it?” Dr. Eric Topol, cardiologist and chief academic officer at Scripps Health in LaJolla, Calif., asked the newspaper, adding that the reduced hospitalization rate reported in the study “may actually present a net reduction in costs from a societal standpoint.”

But Dr. William Abraham, chief of cardiology at Ohio State University, said the lower death rate will mean increased adoption no matter the cost. Abraham was the lead investigator on a Medtronic CRT-D study 10 years ago, according to the newspaper.

“There will be no way to keep the floodgates closed,” he told the Journal.

Here’s a roundup of recent clinical trial news:

  • HeartWare achieves primary endpoint with 92% success in pivotal bridge-to-transplant clinical trial, ADVANCE
    HeartWare International Inc. (NSDQ:HTWR) announced that data from its pivotal bridge-to-heart-transplantation study, ADVANCE, showed that 92 percent of the investigational device patients met the per protocol primary endpoint of the trial, which was defined as alive on the originally implanted device, transplanted or explanted for recovery at 180 days.
    Read more
  • Boston Scientific begins patient enrollment in clinical trial assessing deep-brain stimulation for Parkinson’s disease
    Boston Scientific Corp. (NYSE:SX) today announced the first implantation of its Vercise™ deep-brain stimulation system as part of the VANTAGE clinical trial. VANTAGE is a multi-center, prospective trial designed to examine the improvement of motor function in approximately 40 European patients implanted with the Vercise DBS System for the treatment of Parkinson’s disease.
    Read more
  • A new solar-powered blood pressure measuring device for low-resource settings
    The management of high blood pressure is particularly inadequate in low-income countries, where the unavailability of a reliable, durable, and affordable BP-measurement device is a major obstacle to accurate diagnosis. Recognizing this, a World Health Organization committee was established to correct this deficiency by influencing manufacturers to produce a device according to predetermined criteria and to demonstrate the suitability of the device for low resource settings. A device, which fulfilled stipulated criteria in being inexpensive, semiautomated, and solar powered, was validated according to the International Protocol of the European Society of Hypertension; it was then subjected to field testing in 716 subjects from 2 centers in Uganda and 1 in Zambia.
    Read more
  • Seven U.S. medical centers begin study to change femoral artery cath lab access
    Patient enrollment has begun in the RECITAL (A Patient Registry Evaluating Closure Following Access with the Arstasis One Access System) Study. The non-randomized, prospective, post-approval study is anticipated to enroll up to 500 patients in at least seven U.S. hospitals. The goal of the study is to observe the clinical safety and effectiveness of the Arstasis One Access System in patients undergoing diagnostic angiography procedures through the femoral artery.
    Read more
  • BioControl wins IDE approval for INOVATE-HF study
    BioControl Medical announced Food & Drug Administration conditional approval for its Investigational Device Exemption application and pivotal clinical trial protocol to begin evaluating the CardioFit system for the treatment of congestive heart failure. The company will begin enrollment in the INOVATE-HF (INcrease Of VAgal TonE in chronic Heart Failure) clinical trial.
    Read more
  • NICOM system for noninvasive hemodynamic monitoring found to be an effective tool for identification of acute heart failure in the emergency department
    A study performed by investigators from the Emergency Department of the Cleveland Clinic Foundation, published in the American Journal of Emergency Medicine, finds that Cheetah Medical’s NICOM system is effective in identification of acute heart failure and in differentiating it from other acute situations with similar clinical presentations.
    Read more
  • Flexible Stenting Solutions presents first-in-man clinical experience with the FlexStent femoropopliteal SE stent system
    Final first-in-man clinical results on the use of the FlexStent femoropopliteal SE stent system were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions Inc.’s FIM study, conducted in New Zealand by principle investigator Dr. Andrew Holden, and FSS’s supplementary study conducted in Germany by principle investigator Dr. Dierk Scheinert of University of Leipzig – Heart Center.
    Read more
  • Miracor reports successful first-in-man clinical outcome for its PICSO system
    Miracor Medical Systems GmbH announced today the successful first-in-man clinical outcome for its Pressure-controlled Intermittent Coronary Sinus Occlusion System, designed to improve acute coronary syndrome revascularization following primary percutaneous coronary intervention.
    Read more
  • Non-invasive glucose measurements in the eye highly effective in clinical study
    Freedom Meditech Inc. announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose measurements in the eye in a live animal model.
    Read more
  • Stem cell study shows benefits in treatment of spinal injuries
    Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented the summary results of a retrospective clinical study of human embryonic stem cell therapy in patients with chronic spinal cord injury at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010.
    Read more
  • Results of two new clinical studies show promise of Mobile Health to combat obesity epidemic
    BodyMedia Inc. recently announced the findings from two clinical studies that yielded promising results showcasing body monitoring devices’ integral role in the current public health dialogue.
    Read more
  • Interleukin Genetics and the University of North Carolina at Chapel Hill announce additional clinical study findings on osteoarthritis progression
    Interleukin Genetics Inc. (OTC:ILIU) and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today additional findings from their previously reported 1,154-patient longitudinal study to evaluate the role of genetic factors in osteoarthritis progression.
    Read more
  • US HIFU announces that 18 recurrent prostate cancer clinical trial sites are open for enrollment
    USHIFU LLC announced that 18 clinical trial sites involved in the recurrent prostate cancer trial have been initiated and opened.
    Read more

Filed Under: Business/Financial News, News Well Tagged With: Clinical Trials

In case you missed it

  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment
  • BD launches automated infectious disease diagnostic platform in the U.S.
  • DarioHealth rises on Street-beating Q1
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
  • Moderna’s new CFO leaves after former employer discloses investigation
  • How technology is changing the operating room

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS